Global Oncology Academy

Poster Pearl: Imaging-Based Localization for MCED Tests Yields Lower Diagnostic Burden

ReachMD Healthcare Image

Dive into the key findings from a poster that was presented at the 2023 American Association for Cancer Research Annual Meeting.

  • Overview

    Blood-based multi-cancer early detection (MCED) tests are currently being developed to increase the number of cancers that can be detected in adults, but it requires the localization of the tissue of origin (TOO) in patients with cancer-suspected results using either molecular- or imaging-based strategies. To better understand the diagnostic burden associated with these MCED TOO localization strategies, a poster presented at the 2023 American Association for Cancer Research Annual Meeting evaluated published research and found that imaging-based localization had a lower diagnostic burden. Dive further into the results with Dr. Betsy O’Donnell, co-author of the poster and Director of Early Detection and Prevention of Malignant Conditions at the Dana-Farber Cancer Institute.

    This is a non-certified educational series produced and controlled by ReachMD. This series is intended for healthcare professionals only. This program discusses a technology under development. Any features discussed describe current development goals. It has not been cleared or approved by the U.S. FDA or any other national regulatory authority.

Facebook Comments



We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free